1. United Nations Office on Drugs and Crime. New psychoactive substances (NPS). [Electronic resource]. Available at: https://www.unodc.org/documents/scientific/NPS_leaflet_2016_Russian.pdf. 2. Varì M.R., Mannocchi G., Tittarelli R., Campanozzi L.L., Nittari G., Feola A., Ronchi F.U., Ricci G. New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union. Int. J. Environ. Res. Public Health. 2020;17:8704. 3. Schifano F. Recent Changes in Drug Abuse Scenarios: The New/Novel Psychoactive Substances (NPS) Phenomenon. Brain Sci 2018; (8):221. 4. European Monitoring Center for Drug and Drug Addiction. European Drug Report 2023. Trends and Development. [Electronic resource]. Available at: https://www.emcdda.europa.eu/publications/european-drug-report/2023/new-psychoactive-substances_en 5. Asadullin A.R., Achmetova E.A., Galeeva E.K., Nikolaev I.V. Approach to classifying "design" drugs and new potentially dangerous chemical substances, with a brief review of the problem. International Journal of Environmental and Science Education 2016; 11(14):6697-6703. 6. Asadullin A.R., Galeeva E.Kh., Lisovskaya S.B., Akhmetova E.A., Nikolaev I.V. Systematization of synthetic “designer” drugs and new potentially dangerous chemicals. Narcology 2017; 16(3):94-10 7. Information on drug-related situation in the Republic of Uzbekistan in 2019. [Electronic resource]. Available at: https://ncdc.uz/uploads/image/17122020-110017_551-6.pdf 8. https://repost.uz/stali-chasto-provozit-sintetiku 9. Ageely H.M.A. Health and socio-economic hazards associated with Khat consumption. Journal of Family and Community Medicine 2008; (15):3–11 10. Mas-Morey, P.; Visser, M.H.M.; Winkelmolen, L.; Touw, D.J. Clinical toxicology and management of intoxications with synthetic cathinones (“bath salts”). J. Pharm. Pract. 2012, 26, 353–357. 11. Dumestre-Toulet, V.; Brault, S.; Labadie, M.; Penouil-Pucheu, F. Madness with five dollars: Two new cases of non-lethal poisoning flakka (α-PVP). Toxicol. Anal. Clin. 2017, 29, 111–116. 12. Murray, B. L.; Murphy, C. M.; Beuhler, M.C. Death following recreational use of designer drug “bath salts” containing 3, 4-methylenedioxypyrovalerone (MDPV). J. Med. Toxicol. 2012, 8, 69–75. 13. Kesha, K.; Boggs, C. L.; Ripple, M. G.; Allan, C. H.; Levine, B.; Jufer-Phipps, R.; Doyon, S.; Chi, P. L.; Fowler, D.R. Methylenedioxypyrovalerone (“bath salts”), related death: Case report and review of the literature. J. Forensic Sci. 2013, 58, 1654–1659. 14. Desharnais, B.; Dazé, Y.; Huppertz, L. M.; Mireault, P.; Skinner, C.D. A case of fatal idiosyncratic reaction to the designer drug 3, 4-methylenedioxypyrovalerone (MDPV) and review of the literature. Forensic Sci. Med. Pathol. 2017, 13, 350–354. 15. Luethi, D.; Liechti, M.E. Mechanism of action Designer drugs and adverse effects. Arch. Toxicol. 2020, 94, 1085–1133. 16. Zaami, S.; Giorgetti, R.; Pichini, S.; Pantano, F.; Marinelli, E.; Busardò, F.P. Synthetic cathinones related fatalities: An update. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 268–274. 17. Winstock, A.R.; Mitcheson, L.R.; Deluca, P.; Davey, Z.; Corazza, O.; Schifano, F. Mephedrone, new kid for the chop? Addiction 2011, 106, 154–161. 18. Glennon, R.A. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol. 2014, 69, 581–620. 19. Gibbons, S.; Zloh, M. An analysis of the ‘legal high’ mephedrone. Bioorg. Med. Chem. Lett. 2010, 20, 4135–4139. 20. Spiller, H. A.; Ryan, M. L.; Weston, R. G.; Jansen, J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin. Toxicol. 2011, 49, 499–505. 21. Fass, J. A.; Fass, A. D.; Garcia, A.S. Synthetic cathinones (bath salts): Legal status and patterns of abuse. Ann. Pharmacother. 2012, 46, 436–441. 22. Prosser, J. M.; Nelson, L.S. The toxicology of bath salts: A review of synthetic cathinones. J. Med. Toxicol. 2012, 8, 33–42. 23. Bronstein, A.C.; Spyker, D. A.; Cantilena, L.R., Jr.; Green, J. L.; Rumack, B. H.; Dart, R.C. 2010 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 28th Annual Report. Clin. Toxicol. 2011, 49, 910–941. 24. Gummin, D. D.; Mowry, J.B.; Spyker, D. A.; Brooks, D. E.; Fraser, M.O.; Banner, W. 2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report. Clin. Toxicol. 2017, 55, 1072–1552. 25. James, D.; Adams, R. D.; Spears, R.; Cooper, G.; Lupton, D. J.; Thompson, J.P.; Thomas, S.H.L. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg. Med. J. 2011, 28, 686–689. 26. EMCDDA. European Monitoring Center for Drugs and Drug Addiction. EMCDDA-Europol Joint Report on a New Psychoactive Substance: 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP). 2015. Available online: http://www.emcdda.europa.eu/publications/joint-reports/alpha-pvp_en (accessed on 1 September 2015). 27. German, C. L.; Fleckenstein, A.E.; Hanson, G.R. Bath salts and synthetic cathinones: An emerging designer drug phenomenon. Life Sci. 2014, 97, 2–8. 28. Watterson, L.R.; Kufahl, P. R.; Nemirovsky, N.E.; Sewalia, K.; Grabenauer, M.; Thomas, B.F.; Marusich, J. A.; Wegner, M.; Olive, M.F. Potent rewarding and reinforcing effects of the synthetic cathinone 3, 4-methylenedioxypyrovalerone (MDPV). Addict. Biol. 2014, 19, 165–174. 29. Karila, L.; Megarbane, O.; Lejoyeux, B.; Cottencin, M. Synthetic cathinones: A new public health problem. Curr. Neuropharmacol. 2015, 13, 12–20. 30. Weinstein, A. M.; Rosca, P.; Fattore, L.; London, E.D. Synthetic cathinone and cannabinoid designer drugs pose a major risk for public health. Front. Psychiatry 2017, 8, 156. 31. Al-Hebshi, N.N.; Skaug, N. Khat (Catha edulis)—An updated review. Addict. Biol. 2005, 10, 299–307. 32. Sauer, C.; Peters, F. T.; Haas, C.; Meyer, M.R.; Fritschi, G.; Maurer, H.H. New designer drug a-pyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrum. 2009, 44, 952–964. 33. Marinetti, L.J.; Antonides, H.M. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: Method of development, drug distribution and interpretation of results. J.Anal. Toxicol. 2013, 37, 135–146. 34. DiSalvo, D. The Backstory You Really Need to Know about Flakka and Other Synthetic Drugs. Forbes Magazine. 2015. Available online: https://www.forbes.com/sites/daviddisalvo/2015/04/15/the-backstory-you-really-need-to-know-about-flakka-and-other-synthetic-drugs /#369ec24a4a4d 35. Crespi, C. Flakka-induced prolonged psychosis. Case Rep. Psychiatry 2016, 2016, 3460849. 36. Gómez-Arnau, J.; Rodriguez-Salgado, B.; Sánchez-Mateos, D.; Dolengevich-Segal, H. FLAKKA: Una nueva droga psicoactiva en España. Revista. Patol. Dual. 2015, 2, 6–7. 37. Gussow, L. Toxicology rounds: Flakka: Illicit drug triggering bizarre behavior. Emerg. Med. News. 2015, 37, 24. 38. Beck, O.; Franzen, L.; Bäckberg, M.; Signell, P.; Helander, A. Toxicity evaluation of α-pyrrolidinovalerophenone (α-PVP): Results from intoxication cases within the STRIDA project. Clin. Toxicol. 2016, 54, 568–575. 39. Katselou, M.; Papoutsis, I.; Nikolaou, P.; Spiliopoulou, C.; Athanaselis, S. α-PVP (“flakka”): A new synthetic cathinone invades the drug arena. Forensic Toxicol. 2016, 34, 41–50. 40. Aarde, S. M.; Huang, P. K.; Creehan, K. M.; Dickerson, T. J.; Taffe, M.A. The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: Self-administration and locomotor activity in rats. Neuropharmacology 2013, 71, 130–140. 41. Rickli, A.; Hoener, M.C.; Liechti, M.E. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol. 2015, 25, 365–376. 42. Simmler, L.D.; Buser, T. A.; Donzelli, M.; Schramm, Y.; Dieu, L.-H.; Huwyler, J.; Chaboz, S.; Hoener, M.C.; Liechti, M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol. 2013, 168, 458–470. 43. Meltzer, P.C.; Butler, D.; Deschamps, J.R.; Madras, B.K. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogs: A promising class of monoamine uptake inhibitors. J. Med. Chem. 2006, 49, 1420–1432. 44. Naylor, J. E.; Freeman, K. B.; Blough, B. E.; Woolverton, W. L.; Huskinson, S. L. Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug Alcohol. Depend. 2015, 149, 280–284. 45. Kaizaki, A.; Tanaka, S.; Numazawa, S. New recreational drug 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (alpha-PVP) activates central nervous system via dopaminergic neuron. J. Toxicol. Sci. 2014, 39, 1–6. 46. Marusich, J. A.; Antonazzo, K.R.; Wiley, J.L.; Blough, B. E.; Partilla, J.S.; Baumann, M.H. Pharmacology of novel synthetic stimulants is structurally related to the “bath salts” constituent 3,4-methylenedioxypyrovalerone (MDPV). Neuropharmacology 2014, 87, 206–213. 47. Gatch, M.B.; Dolan, S.B.; Forster, M. J. Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J. Pharmacol. Exp. Ther. 2015, 354, 103–110. 48. Gannon, B. M.; Baumann, M.H.; Walther, D.; Jimenez-Morigosa, C.; Sulima, A.; Rice, K.C.; Collins, G.T. The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. Neuropsychopharmacology 2018, 43, 2399–2407. 49. Collins, G. T.; Sulima, A.; Rice, K.C.; France, C.P. Self-administration of the synthetic cathinones 3,4-methylenedioxypyrovalerone (MDPV) and α-pyrrolidinopentiophenone (α-PVP) in rhesus monkeys. Psychopharmacology 2019, 236, 3677–3685. 50. Zhou, X.; Luethi, D.; Sanvee, G. M.; Bouitbir, J.; Liechti, M. E.; Krähenbühl, S. Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. Int. J. Mol. Sci. 2019, 20, 1561. 51. Kolesnikova, T.O.; Khatsko, S.L.; Demin, K.A.; Shevyrin, V.A.; Kalueff, A.V. DARK Classics in Chemical Neuroscience: α-Pyrrolidinovalerophenone (“Flakka”). ACS Chem. Neurosci. 2019, 10, 168–174. 52. Kolesnikova, T.O.; Khatsko, S. L.; Eltsov, O.S.; Shevyrin, V.A.; Kalueff, A.V. When fish take a bath: Psychopharmacological characterization of the effects of a synthetic cathinone bath salt ‘flakka’ on adult zebrafish. Neurotoxicol. Teratol. 2019, 73, 15–21. 53. World Anti-Doping Agency. List of Prohibited Substances and Methods. Cathinone and Its Analogues (e.g., Mephedrone, Methedrone, α-pyrrolidinovalerophenone). 2016. Available online: http://list.wada-ama.org/list/s6-stimulants/cathinone-and-its-analogues-e-g-mephedrone-methedrone-%CE%B1-pyrrolidinovalerophenone/ 54. Haas, C.; Sauer, C.; Meyer, M.R.; Fritschi, G.; Maurer, H. H.; Peters, F.T. Studies on the metabolism and toxicological analysis of the new designer drug a-pyrrolidinovalerophenone (PVP) in rat urine using GC-MS techniques. In Current Contributions to Forensic and Clinical Toxicology; Pragst, F., Aderjan, R., Eds.; GTFCH: Bad Vilbel, Germany, 2008; pp. 269–276. 55. Negreira, N.; Erratico, C.; Kosjek, T.; van Nuijs, A.L.N.; Heath, E.; Neels, H.; Covaci, A. In vitro Phase I and Phase II metabolism of a-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol. Anal. Bioanal. Chem. 2015, 407, 5803–5816. 56. Shima, N.; Katagi, M.; Kamata, H.; Matsuta, S.; Sasaki, K.; Kamata, T.; Nishioka, H.; Miki, A.; Tatsuno, M.; Zaitsu, K.; et al. Metabolism of the newly encountered designer drug a-pyrrolidinovalerophenone in humans: Identification and quantitation of urinary metabolites. Forensic Toxicol. 2014, 32, 59–67. 57. Hasegawa, K.; Suzuki, O.; Wurita, A.; Minakata, K.; Yamagishi, I.; Nozawa, H.; Gonmori, K.; Watanabe, K. Postmortem distribution of a-pyrrolidinovalerophenone and its metabolite in body fluids and solid tissues in a fatal poisoning case measured by LC-MS-MS with the standard addition method. Forensic Toxicol. 2014, 32, 225–234. 58. Banks, M. L.; Worst, T. J.; Rusyniak, D. E.; Sprague, J.E. Synthetic cathinones (“bath salts”). J. Emerg. Med. 2014, 46, 632–642. 59. Marusich, J. A.; Lefever, T. W.; Blough, B. E.; Thomas, B.F.; Wiley, J.L. Pharmacological effects of methamphetamine and alpha-PVP vapor and injection. Neurotoxicology 2016, 55, 83–91. 60. Heikman, P.; Sundström, M.; Pelander, A.; Ojanperä, I. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening. Hum. Psychopharmacol. 2016, 31, 44–52. 61. Palamar, J. J.; Rutherford, C.; Keyes, K.M. “Flakka” use among high school seniors in the United States. Drug Alcohol. Depend. 2019, 196, 86–90. 62. Wiese Simonsen, K.; Edvardsen, H.M.E.; Thelander, G.; Ojanpera, I.; Thordardottir, S.; Andersen, L.V.; Kriikku, P.; Vindenes, V.; Christoffersen, D.; Delaveris, G. J. M.; et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci. Int. 2015, 248, 172–180. 63. Franzen, L.; Bäckberg, M.; Beck, O.; Helander, A. Acute intoxications involving α-pyrrolidinobutiophenone (α-PBP): Results from the Swedish STRIDA Project. J. Med. Toxicol. 2018, 14, 265–271. 64. EMCDDA. European Monitoring Center for Drugs and Drug Addiction. EMCDDA–Europol Joint Report on a New Psychoactive Substance: MDPV (3,4-methylenedioxypyrovalerone); In Accordance with Article 5 of Council Decision 2005/387/JHA on the Information Exchange, Risk Assessment and Control of New Psychoactive Substances; EMCDDA: Lisbon, Portugal, 2014. 65. Richards-Waugh, L.L.; Bailey, K. M.; Clay, D. J.; Gebhardt, M.A.; Newsome-Sparks, C. L.; Mahmoud, H. E.; Venuti, S. E.; Kraner, J.C. Deaths involving the recreational use of α-PVP (α-pyrrolidinopentiophenone). AAFS Proc. 2013, 16, 521–522. 66. Saito, T.; Namera, A.; Osawa, M.; Aoki, H.; Inokuchi, S. SPME-GC-MS analysis of a-pyrrolidinovalerophenone in blood in a fatal poisoning case. Forensic Toxicol. 2013, 31, 328–332. 67. Nagai, H.; Saka, K.; Nakajima, M.; Maeda, H.; Kuroda, R.; Igarashi, A.; Tsujimura-Ito, T.; Nara, A.; Komori, M.; Yoshida, K. Sudden death after sustained restraint following self administration of the designer drug a-pyrrolidinovalerophenone. Int. J. Cardiol. 2014, 172, 263–265. 68. Minakata, K.; Yamagishi, I.; Nozawa, H.; Hasegawa, K.; Wurita, A.; Gonmori, K.; Suzuki, M.; Watanabe, K.; Suzuki, O. MALDITOF mass spectrometric determination of four pyrrolidino cathinones in human blood. Forensic Toxicol. 2014, 32, 169–175. 69. Robles, F. Police in Florida Grapple with a Cheap and Dangerous New Drug. New York Times. 2014. Available online: http://www.nytimes.com/2015/05/25/us/police-in-florida-grapple-with-flakka-a-cheap-anddangerous-new-drug.html?_r=0